Latest Anticonvulsant Stories

Leading Philanthropists, Celebrity, Experts and People with Epilepsy Serve as Judges at Antiepileptic Drug and Device Trials (AED) XII and Pipeline Conference MIAMI, May 17, 2013 /PRNewswire-USNewswire/ -- The Epilepsy Foundation today announced the 2013 winner of the Epilepsy Therapy Project Second Annual "Shark Tank" competition for the most innovative new product idea for people with epilepsy. Utkan Demirci, Ph.D. and Steven C. Schachter, MD designed a novel point of care...

--Data Presented at AED Xll Meeting Confirms INS001 Appears Safe and Well Tolerated-- MIAMI, May 17, 2013 /PRNewswire/ -- Insero Health, Inc., a company developing natural compounds to address unmet medical needs in epilepsy and related neurological disorders, is today reporting top-line results from a Phase Ib trial of its lead compound INS001 in patients with drug-resistant epilepsy. The data are being presented at the AntiEplileptic Drug and Device Trials (AED) Xll meeting...

NIH-supported study suggests cell therapy may be a viable approach More than two million people in the United States suffer from epilepsies, a group of neurological disorders caused by abnormal nerve cell firing in the brain which often produce debilitating seizures. Although anti-epileptic drugs and other therapies reduce seizures in about two-thirds of patients, the remaining one-third do not respond to any form of therapy and those who take drugs can experience harmful side effects. NIH...

UCLA Case Study Results To Be Presented At Major International Status Epilepticus Conference In Salzburg, Austria LOS ANGELES, March 25, 2013 /PRNewswire/ -- NeuroSigma, Inc., a California-based medical device company, today announced that it will exhibit its CE Mark approved, non-invasive Monarch(TM) eTNS(TM) System for the adjunctive treatment of epilepsy and depression, at the 4th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures to be held in Salzburg, Austria...

MAPLE GROVE, Minn., March 11, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), a privately held, specialty pharmaceutical company committed to the development of new treatments for diseases of the central nervous system (CNS), is proud to sponsor emerging data for three investigational drug programs in epilepsy at the 65(th) Annual Meeting of the American Academy of Neurology (AAN) in San Diego, CA, March 16-23, 2013. Upsher-Smith's CNS pipeline consists of...

MAPLE GROVE, Minn., Jan. 14, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. [http://www.upsher-smith.com] today announced that its epilepsy-focused educational website, Epilog.us [http://www.Epilog.us], now features a panel discussion of leading experts on the role of rational polytherapy in the treatment of patients with epilepsy, led by Dr. Barry Gidal, Professor of Pharmacy and Neurology/Division Chair, University of Wisconsin. Dr. Gidal also brings forward discussion on...

MIAMI, Dec. 13, 2012 /PRNewswire/ -- Insero Health, Inc., a company developing natural compounds to address unmet medical needs in neurological disorders, today announced that it has completed a Phase Ib trial of its lead compound INS001 in patients with drug-resistant epilepsy. Insero also reported that two key US patents licensed from Harvard University have issued, and the company announced the formation of its Scientific Advisory Board (SAB). INS001, also known as huperzine A,...

MAPLE GROVE, Minn., Nov. 27, 2012 /PRNewswire/ -- Approximately 1.5 million women and girls in the United States have epilepsy, of which nearly 500,000 are women of childbearing age.(1,2) Treating women with epilepsy, especially women of childbearing age, presents significant challenges to physicians. Epilog.us [http://www.epilog.us], Upsher-Smith Laboratories, Inc's [http://www.upsher-smith.com] epilepsy-focused educational website, discusses these challenges and provides...

MAPLE GROVE, Minn., Nov. 26, 2012 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith) a privately held, specialty pharmaceutical company committed to the development of new treatments for diseases of the central nervous system, is proud to sponsor emerging data on USL261, its novel formulation of intranasal midazolam, at the 66(th) Annual Meeting of the American Epilepsy Society (AES) in San Diego, CA, November 30 - December 4, 2012. "Upsher-Smith is committed to working...

New drugs derived from components of a specific diet used by children with severe, drug-resistant epilepsy could offer a new treatment, according to research published today in the journal Neuropharmacology. Scientists from Royal Holloway, in collaboration with University College London, have identified specific fatty acids that have potent antiepileptic effects, which could help control seizures in children and adults. The discovery could lead to the replacement of the ketogenic diet,...